Langer, C.; Köll-Weber, M.; Holzer, M.; Hantel, C.; Süss, R.
Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids. Pharmaceutics 2022, 14, 1891.
https://doi.org/10.3390/pharmaceutics14091891
AMA Style
Langer C, Köll-Weber M, Holzer M, Hantel C, Süss R.
Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids. Pharmaceutics. 2022; 14(9):1891.
https://doi.org/10.3390/pharmaceutics14091891
Chicago/Turabian Style
Langer, Carolin, Monika Köll-Weber, Martin Holzer, Constanze Hantel, and Regine Süss.
2022. "Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids" Pharmaceutics 14, no. 9: 1891.
https://doi.org/10.3390/pharmaceutics14091891
APA Style
Langer, C., Köll-Weber, M., Holzer, M., Hantel, C., & Süss, R.
(2022). Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids. Pharmaceutics, 14(9), 1891.
https://doi.org/10.3390/pharmaceutics14091891